Display options
Cite
Bota DA, Desjardins A, Quinn JA, et al. Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas. Ther Clin Risk Manag. 2007;3(5):707-15
Bota, D. A., Desjardins, A., Quinn, J. A., Affronti, M. L., & Friedman, H. S. (2007). Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas. Therapeutics and clinical risk management, 3(5), 707-15.
Bota, Daniela A, et al. "Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas." Therapeutics and clinical risk management vol. 3,5 (2007): 707-15.
Bota DA, Desjardins A, Quinn JA, Affronti ML, Friedman HS. Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas. Ther Clin Risk Manag. 2007 Oct;3(5):707-15. PMID: 18472995; PMCID: PMC2376068.
Copy Download .nbib Format: NLM
Share it on

Ther Clin Risk Manag. 2007 Oct;3(5):707-15.

Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas.

Therapeutics and clinical risk management

Daniela A Bota, Annick Desjardins, Jennifer A Quinn, Mary L Affronti, Henry S Friedman

Affiliations

  1. The Preston Robert Tisch Brain Tumor Center, Duke University Medical Center Durham, NC, USA.

PMID: 18472995 PMCID: PMC2376068

Abstract

Malignant gliomas represent the majority of primary brain tumors, and the prognosis of the patients afflicted with these tumors has been historically dismal, with almost uniform progressive neurologic impairment and rapid death. Even with multimodal treatment using surgery, focal radiation, and chemotherapy, no major strides were made until recently. The development of interstitial BCNU wafers (carmustine wafers, Gliadel((R))) has led to promising results in the treatment of a selected patients with malignant gliomas, as well as with other intracranial malignancies.BCNU is one of the first systemic chemotherapies which had obtained United States Food and Drug Administration (FDA) approval for the treatment of brain tumors. However, systemic use has been hampered by the modest prolongation of survival and by the prolonged myelosuppression and potentially fatal pulmonary toxicity. The development of interstitial therapies with BCNU represented a great step forward, allowing direct delivery to the tumor bed, with virtually no systemic toxicities. Clinical studies of BCNU wafers have showed good efficacy in both newly diagnosed and recurrent gliomas, as well as a possible therapeutic role in other primary or secondary intracranial malignancies. New studies are currently underway trying to improve the efficacy of the BCNU wafers (Gliadel((R))) by combining them with different systemic chemotherapies. An overview of the current knowledge ranging from the preclinical developments, to the efficacy and safety seen in the clinical trials and in clinical practice following the drug approval to the future avenues of research is therefore timely.

Keywords: BCNU; Gliadel® wafers; interstitial therapy; malignant gliomas

References

  1. Biochemistry. 1976 Jun 15;15(12):2661-8 - PubMed
  2. Neurosurgery. 2003 Aug;53(2):255-69; discussion 259-60 - PubMed
  3. Cancer Treat Rev. 1981 Jun;8(2):111-25 - PubMed
  4. Lancet Oncol. 2001 Aug;2(8):483-90 - PubMed
  5. Cancer Res. 1963 Jun;23:725-33 - PubMed
  6. Clin Cancer Res. 2007 Jun 15;13(12):3637-41 - PubMed
  7. Neuro Oncol. 2005 Jan;7(1):84-9 - PubMed
  8. Cancer Res. 1977 May;37(5):1450-4 - PubMed
  9. Clin Pharmacol Ther. 1967 Jul-Aug;8(4):566-77 - PubMed
  10. Neurosurgery. 1997 Jul;41(1):44-8; discussion 48-9 - PubMed
  11. Cancer Invest. 2004;22(1):1-9 - PubMed
  12. N Engl J Med. 1990 Feb 22;322(8):494-500 - PubMed
  13. Cancer Res. 1978 Aug;38(8):2363-6 - PubMed
  14. Neurosurg Focus. 2006 Apr 15;20(4):E3 - PubMed
  15. Neurosurgery. 2003 Apr;52(4):872-9; discussion 879-80 - PubMed
  16. Cancer Res. 1993 Jan 15;53(2):329-33 - PubMed
  17. Br J Neurosurg. 2003 Aug;17(4):352-4 - PubMed
  18. Prog Nucleic Acid Res Mol Biol. 1995;51:167-223 - PubMed
  19. J Pharmacol Exp Ther. 1975 Oct;195(1):73-83 - PubMed
  20. J Natl Cancer Inst. 1982 Apr;68(4):541-7 - PubMed
  21. J Neuropathol Exp Neurol. 2005 Jun;64(6):479-89 - PubMed
  22. Acta Neurochir (Wien). 2007 Mar;149(3):261-5; discussion 265 - PubMed
  23. Clin Cancer Res. 2004 Mar 15;10(6):1871-4 - PubMed
  24. Cancer Treat Rep. 1976 Jun;60(6):665-98 - PubMed
  25. Biomaterials. 1995 Sep;16(14):1069-72 - PubMed
  26. Chest. 1977 Sep;72(3):372-3 - PubMed
  27. Neuro Oncol. 2001 Oct;3(4):246-50 - PubMed
  28. J Natl Cancer Inst. 1992 Dec 16;84(24):1926-31 - PubMed
  29. Cancer Treat Rep. 1981 Jan-Feb;65(1-2):39-44 - PubMed
  30. J Biomed Mater Res. 1994 Mar;28(3):387-95 - PubMed
  31. J Neurooncol. 2005 May;72(3):241-4 - PubMed
  32. J Clin Oncol. 2007 Feb 1;25(4):399-404 - PubMed
  33. Neurosurgery. 1998 Nov;43(5):1185-93 - PubMed
  34. Cancer Lett. 1987 Aug;36(2):131-7 - PubMed
  35. J Clin Oncol. 1998 Dec;16(12):3851-7 - PubMed
  36. Neuro Oncol. 2003 Apr;5(2):79-88 - PubMed
  37. J Neurooncol. 2006 Mar;77(1):47-51 - PubMed
  38. Cancer Chemother Pharmacol. 1993;32(6):471-6 - PubMed
  39. Clin Infect Dis. 2003 Mar 15;36(6):759-65 - PubMed
  40. J Neurosurg. 1994 Feb;80(2):283-90 - PubMed
  41. Cancer Treat Rep. 1976 Jun;60(6):703-7 - PubMed
  42. Cancer Res. 1965 Dec;25(11):1876-81 - PubMed
  43. Cancer Res. 1976 Apr;36(4):1470-4 - PubMed
  44. DNA Repair (Amst). 2004 Nov 2;3(11):1389-407 - PubMed
  45. Neurosurgery. 2002 Aug;51(2):343-55; discussion 355-7 - PubMed
  46. J Neurooncol. 1995 Nov;26(2):111-23 - PubMed
  47. J Neurosurg. 1991 Mar;74(3):441-6 - PubMed
  48. Cancer Treat Rev. 1982 Dec;9(4):313-30 - PubMed
  49. Cancer Res. 2000 Nov 15;60(22):6307-10 - PubMed
  50. Clin Cancer Res. 2009 Feb 1;15(3):1064-8 - PubMed
  51. J Neurosurg. 2002 May;96(5):941-5 - PubMed
  52. Lancet. 2002 Mar 23;359(9311):1011-8 - PubMed
  53. Clin Oncol. 1975 Sep;1(3):213-22 - PubMed
  54. J Clin Oncol. 2003 May 1;21(9):1845-9 - PubMed
  55. Cancer Chemother Rep 3. 1973 May;4(3):3-6 - PubMed
  56. Cancer Res. 1989 Sep 15;49(18):5103-7 - PubMed
  57. Cancer Treat Rep. 1976 Sep;60(9):1257-61 - PubMed
  58. Adv Cancer Res. 1972;16:273-332 - PubMed
  59. J Neurosurg. 1992 Apr;76(4):640-7 - PubMed
  60. Cancer Res. 1996 Nov 15;56(22):5217-23 - PubMed
  61. Cancer Treat Rep. 1983 Feb;67(2):121-32 - PubMed
  62. Expert Opin Biol Ther. 2005 Apr;5(4):477-94 - PubMed
  63. J Clin Oncol. 1998 Nov;16(11):3570-5 - PubMed
  64. Acta Neurochir (Wien). 2006 Mar;148(3):269-75; discussion 275 - PubMed
  65. Clin Pharmacokinet. 2002;41(6):403-19 - PubMed
  66. Pharm Res. 1996 May;13(5):683-91 - PubMed
  67. Lancet. 1995 Apr 22;345(8956):1008-12 - PubMed
  68. JAMA. 1998 Nov 4;280(17):1485-9 - PubMed
  69. Blood. 1985 Jun;65(6):1364-72 - PubMed
  70. Cancer. 1983 Sep 15;52(6):997-1007 - PubMed
  71. N Engl J Med. 2005 Mar 10;352(10):987-96 - PubMed
  72. J Med Chem. 1963 Nov;6:669-81 - PubMed
  73. Cancer Treat Rep. 1976 Jun;60(6):647-9 - PubMed
  74. J Neurooncol. 2004 Feb;66(3):351-60 - PubMed

Publication Types